Emily C. Martin

2.5k total citations · 1 hit paper
47 papers, 1.8k citations indexed

About

Emily C. Martin is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Emily C. Martin has authored 47 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 15 papers in Oncology and 12 papers in Hematology. Recurrent topics in Emily C. Martin's work include Chronic Lymphocytic Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Cancer survivorship and care (11 papers). Emily C. Martin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Cancer survivorship and care (11 papers). Emily C. Martin collaborates with scholars based in United States, Germany and Canada. Emily C. Martin's co-authors include Esther van Sluijs, B W Martin, Lars Bo Andersen, Ursina Meyer, Susi Kriemler, Rebecca A. Betensky, Xavier Montalbán, Douglas L. Arnold, Rudolph E. Tanzi and Karolina Piasecka‐Stryczynska and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Emily C. Martin

42 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of school-based interventions on physical activity and fitness in children and adolescents: a review of reviews and systematic update

2011 615 citations Emily C. Martin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily C. Martin United States	18	515	465	357	257	217	47	1.8k
Daniel Finkelstein United States	25	643 1.2×	228 0.5×	77 0.2×	261 1.0×	212 1.0×	63	2.8k
Amy M. Shui United States	29	111 0.2×	188 0.4×	121 0.3×	200 0.8×	212 1.0×	140	3.0k
Raymond R. Balise United States	28	575 1.1×	864 1.9×	96 0.3×	599 2.3×	38 0.2×	96	3.1k
Gary Butler United Kingdom	33	762 1.5×	466 1.0×	51 0.1×	83 0.3×	67 0.3×	106	4.1k
Khaled Sarsour United States	27	111 0.2×	190 0.4×	145 0.4×	113 0.4×	20 0.1×	51	2.4k
Clayton W. Schupp United States	26	218 0.4×	221 0.5×	98 0.3×	388 1.5×	18 0.1×	38	3.0k
Ramón Vélez United States	26	208 0.4×	120 0.3×	66 0.2×	763 3.0×	81 0.4×	51	3.0k
Melissa R. Arbuckle United States	17	246 0.5×	93 0.2×	25 0.1×	128 0.5×	80 0.4×	59	3.3k
Henrik Frederiksen Denmark	36	308 0.6×	652 1.4×	34 0.1×	463 1.8×	25 0.1×	193	4.3k
Louise Baxter United Kingdom	24	204 0.4×	343 0.7×	18 0.1×	164 0.6×	140 0.6×	41	2.7k

Countries citing papers authored by Emily C. Martin

Since Specialization

Citations

This map shows the geographic impact of Emily C. Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily C. Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily C. Martin more than expected).

Fields of papers citing papers by Emily C. Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily C. Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily C. Martin. The network helps show where Emily C. Martin may publish in the future.

Co-authorship network of co-authors of Emily C. Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Emily C. Martin. A scholar is included among the top collaborators of Emily C. Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily C. Martin. Emily C. Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arnold, Douglas L., et al.. (2024). Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis. Neurology. 102(5). e208058–e208058. 19 indexed citations

Martin, Emily C., Phoutdavone Phimphasone‐Brady, Lilian Hoffecker, & Russell E. Glasgow. (2022). Psychosocial Interventions for Pain Management in Breast Cancer Survivors: A RE-AIM Evaluation. Journal of Clinical Psychology in Medical Settings. 30(1). 182–196.

Martin, Emily C., et al.. (2021). Psychotropic medications in oncology. Supportive Care in Cancer. 29(11). 6801–6806. 2 indexed citations

Montalbán, Xavier, Douglas L. Arnold, Martin S. Weber, et al.. (2021). Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis (4124). Neurology. 96(15_supplement). 4 indexed citations

Montalbán, Xavier, Douglas L. Arnold, Amit Bar‐Or, et al.. (2020). Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&2) Evaluating the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis (4071). Neurology. 94(15_supplement). 3 indexed citations

Liao, Yue, Jaejoon Song, Michael C Robertson, Emily C. Martin, & Karen Basen‐Engquist. (2019). An Ecological Momentary Assessment Study Investigating Self-efficacy and Outcome Expectancy as Mediators of Affective and Physiological Responses and Exercise Among Endometrial Cancer Survivors. Annals of Behavioral Medicine. 54(5). 320–334. 12 indexed citations

Montalbán, Xavier, Douglas L. Arnold, Martin S. Weber, et al.. (2019). 056 Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study. Journal of Neurology Neurosurgery & Psychiatry. 90(e7). A18.2–A19. 1 indexed citations

Kolva, Elissa, Lilian Hoffecker, & Emily C. Martin. (2019). Suicidal ideation in patients with cancer: A systematic review of prevalence, risk factors, intervention and assessment. Palliative & Supportive Care. 18(2). 206–219. 61 indexed citations

Montalbán, Xavier, Douglas L. Arnold, Martin S. Weber, et al.. (2019). Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study (S56.004). Neurology. 92(15_supplement). 1 indexed citations

10.

Martin, Emily C., et al.. (2019). Chronic pain, health-related quality of life, and employment in working-age cancer survivors. Journal of Cancer Survivorship. 14(2). 179–187. 36 indexed citations

11.

Martin, Emily C., Jaejoon Song, Wendy Demark‐Wahnefried, Elizabeth Lyons, & Karen Basen‐Engquist. (2018). Predictors of enrollment in individual- and couple-based lifestyle intervention trials for cancer survivors. Supportive Care in Cancer. 26(7). 2387–2395. 2 indexed citations

12.

Cox, Matthew G., Karen Basen‐Engquist, Cindy L. Carmack, et al.. (2017). Comparison of Internet and Telephone Interventions for Weight Loss Among Cancer Survivors: Randomized Controlled Trial and Feasibility Study. JMIR Cancer. 3(2). e16–e16. 15 indexed citations

13.

Martin, Emily C., Karen Basen‐Engquist, Matthew G. Cox, et al.. (2016). Interest in Health Behavior Intervention Delivery Modalities Among Cancer Survivors: A Cross-Sectional Study. JMIR Cancer. 2(1). e1–e1. 28 indexed citations

14.

Giovannoni, Gavin, Gıancarlo Comı, Stuart D. Cook, et al.. (2016). Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028). Neurology. 86(16_supplement). 9 indexed citations

15.

Cook, Stuart D., Giancarlo Comi, Peter Rieckmann, et al.. (2016). Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.095). Neurology. 86(16_supplement). 3 indexed citations

16.

Novy, Diane M., et al.. (2016). (387) Effectiveness of splanchnic nerve neurolysis for targeting location of cancer pain: using the pain drawing as an outcome variable. Journal of Pain. 17(4). S71–S72. 1 indexed citations

17.

Martin, Emily C., Alexandra M. Dick, Erica R. Scioli‐Salter, & Karen S. Mitchell. (2015). Impact of a Yoga Intervention on Physical Activity, Self-Efficacy, and Motivation in Women with PTSD Symptoms. The Journal of Alternative and Complementary Medicine. 21(6). 327–332. 19 indexed citations

18.

Martin, Emily C., et al.. (2015). Pilot testing of a mindfulness- and acceptance-based intervention for increasing cardiorespiratory fitness in sedentary adults: A feasibility study. Journal of Contextual Behavioral Science. 4(4). 237–245. 13 indexed citations

19.

Sullivan, James C., Sandra De Meyer, Doug J. Bartels, et al.. (2013). Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. Clinical Infectious Diseases. 57(2). 221–229. 114 indexed citations

20.

Martin, Emily C. & Rebecca A. Betensky. (2005). Testing Quasi-Independence of Failure and Truncation Times via Conditional Kendall's Tau. Journal of the American Statistical Association. 100(470). 484–492. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact